BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

被引：0
作者：
Marcel Ebeling
Mario Scheurer
Andreas Sakkas
Sebastian Pietzka
Alexander Schramm
Frank Wilde
机构：
[1] Academic Hospital of the University of Ulm,Department of Oral and Plastic Maxillofacial Surgery, Military Hospital Ulm
[2] University Hospital Ulm,Department of Oral and Plastic Maxillofacial Surgery
来源：
Medical Oncology | / 40卷
关键词：
Ameloblastoma; BRAF; Facial reconstruction; Chemotherapy; Dabrafenib; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] BRAF-V600E expression correlates with ameloblastoma aggressiveness
    Fregnani, Eduardo R.
    da Cruz Perez, Danyel E.
    de Almeida, Oslei Paes
    Fonseca, Felipe Paiva
    Soares, Fernando A.
    Castro-Junior, Gilberto
    Alves, Fabio A.
    HISTOPATHOLOGY, 2017, 70 (03) : 473 - 484
  • [22] Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
    Francesco Gelsomino
    Alessandro Di Federico
    Maria Lucia Tardio
    Giada Grilli
    Antonietta D’Errico
    Andrea Ardizzoni
    Stefania Salvagni
    Investigational New Drugs, 2022, 40 : 190 - 193
  • [23] Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
    Gelsomino, Francesco
    Di Federico, Alessandro
    Tardio, Maria Lucia
    Grilli, Giada
    D'Errico, Antonietta
    Ardizzoni, Andrea
    Salvagni, Stefania
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 190 - 193
  • [24] Case report: Metastatic BRAF V600E-mutated adult Wilms' tumor with robust response to BRAF/MEK inhibitor therapy
    Kroll, Matthew R.
    Au, Cherry
    Slostad, Jessica
    Christ, Trevor N.
    Papas, Sam G.
    Tan, Alan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E-Mutated Multiple Myeloma
    Sharman, J. P.
    Chmielecki, J.
    Morosini, D.
    Palmer, G. A.
    Ross, J. S.
    Stephens, P. J.
    Stafl, J.
    Miller, V. A.
    Ali, S. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : E161 - E163
  • [26] BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
    Del Bufalo, Francesca
    Ceglie, Giulia
    Cacchione, Antonella
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carai, Andrea
    Diomedi-Camassei, Francesca
    De Billy, Emmanuel
    Agolini, Emanuele
    Mastronuzzi, Angela
    Locatelli, Franco
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [27] Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer
    Farlow, Janice L.
    Mccrary, Hilary C.
    Sipos, Jennifer A.
    Phay, John E.
    Konda, Bhavana
    Agrawal, Amit
    ORAL ONCOLOGY, 2023, 147
  • [28] The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review
    Malakar, Arindam
    Kumar, V. Raj
    Yadav, Priya
    Bhardwaj, Vishal
    Barua, Chuimee Gogoi
    Bhardwaj, Gourika
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [29] BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
    Obasaju, Patience
    Shahab, Shubin
    Dunn, Emily
    Rhee, Daniel S.
    Jiang, LiQun
    Dome, Jeffrey S.
    Friedman, Alan D.
    Argani, Pedram
    Pratilas, Christine A.
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2020, 6 (02):
  • [30] Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity
    Bernstein, Aaron
    Mrowczynski, Oliver D.
    Greene, Amrit
    Ryan, Sandra
    Chung, Catherine
    Zacharia, Brad E.
    Glantz, Michael
    JOURNAL OF NEUROSURGERY, 2020, 133 (06) : 1704 - 1709
12345